Balance sheetWarning
부채총계 급증 (+148%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Forte Biosciences financial statements
NASDAQ:FBRX · Nasdaq$76.99+0.00%
2026-08-28 closeForte Biosciences's published financial data is dated 2026-10-04. 2024 revenue was $0M. 2024 operating profit was −$37M.
Reported results
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.51
Distress
Grey
Safe
- Altman Z''
- -0.51
- Beneish M-Score
- —
- Sloan accrual
- -7.69%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
2/9Weak
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score2/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Quantus Signal · live data · not investment advice · Privacy Policy